Related references
Note: Only part of the references are listed.Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
S. Cuzzubbo et al.
EUROPEAN JOURNAL OF CANCER (2017)
Immunoregulatory functions of VISTA
Elizabeth C. Nowak et al.
IMMUNOLOGICAL REVIEWS (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy
Michael P. Brown et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies
David J. Byun et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma
Simon Bossart et al.
ONCOLOGIST (2017)
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
James Larkin et al.
ONCOLOGIST (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade
Heinz Laubli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
Stephanie Schneider et al.
CASE REPORTS IN ONCOLOGY (2017)
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Arjun Vasant Balar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Eric Tran et al.
NATURE IMMUNOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series
Patrizio Caturegli et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
Lisa Ann Gerdes et al.
ANNALS OF NEUROLOGY (2016)
CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model
Lidia M. Yshii et al.
BRAIN (2016)
Regulatory T cells delay disease progression in Alzheimer-like pathology
Cira Dansokho et al.
BRAIN (2016)
Neurologic complications of immune checkpoint inhibitors
Andreas F. Hottinger
CURRENT OPINION IN NEUROLOGY (2016)
Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma
Yudai Okano et al.
ENDOCRINE JOURNAL (2016)
Rationale for anti-GITR cancer immunotherapy
Deborah A. Knee et al.
EUROPEAN JOURNAL OF CANCER (2016)
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy
Alfonso R. Sanchez-Paulete et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
Edurne Arriola et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
The search for the target antigens of multiple sclerosis, part 2: CD8+T cells, B cells, and antibodies in the focus of reverse-translational research
Reinhard Hohlfeld et al.
LANCET NEUROLOGY (2016)
The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+T lymphocytes as pathogenic effectors and therapeutic targets
Reinhard Hohlfeld et al.
LANCET NEUROLOGY (2016)
Neurological sequelae of cancer immunotherapies and targeted therapies
Wolfgang Wick et al.
LANCET ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease
Kuti Baruch et al.
NATURE MEDICINE (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment
Yonghao Cao et al.
NEUROLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Xiaobo Mao et al.
SCIENCE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4 T Cells to Protect against Autoimmunity
Tony T. Jiang et al.
CELL REPORTS (2016)
Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
Tanya J. Williams et al.
JAMA NEUROLOGY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Acute visual loss after ipilimumab treatment for metastatic melanoma
Melissa A. Wilson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
Jianda Yuan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Peripheral Neuropathy Associated With Ipilimumab
Iyavut Thaipisuttikul et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Innate and adaptive immune responses in the CNS
Ari Waisman et al.
LANCET NEUROLOGY (2015)
Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer
Aaron I. Loochtan et al.
MUSCLE & NERVE (2015)
Tumour necrosis factor receptor superfamily member 9 (TNFRSF9) is up-regulated in reactive astrocytes in human gliomas
A. -E. Blank et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma
Catherine Maurice et al.
CANCER IMMUNOLOGY RESEARCH (2015)
4-1 BB agonists: multi-potent potentiators of tumor immunity
Todd Bartkowiak et al.
FRONTIERS IN ONCOLOGY (2015)
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
Edward J. Gettings et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease
Lawrence Steinman
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development
Avraham Ben-Nun et al.
JOURNAL OF AUTOIMMUNITY (2014)
Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease
Sho Takizawa et al.
JOURNAL OF NEUROIMMUNOLOGY (2014)
An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex
Ye Zhang et al.
JOURNAL OF NEUROSCIENCE (2014)
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
Bing Liao et al.
NEURO-ONCOLOGY (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response
Yuxiang Rui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies A beneficial antitumor immune response going awry
Beatrice S. L. Pignolet et al.
ONCOIMMUNOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis
Christian G. Bien et al.
BRAIN (2012)
Severe meningo-radiculo-nevritis associated with ipilimumab
Flavie Bompaire et al.
INVESTIGATIONAL NEW DRUGS (2012)
Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma
Michela Maur et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Chronic Protective Effects of Limb Remote Preconditioning and the Underlying Mechanisms Involved in Inflammatory Factors in Rat Stroke
Dingtai Wei et al.
PLOS ONE (2012)
Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
S. Wilgenhof et al.
ANNALS OF ONCOLOGY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Role of CD27/CD70 pathway of activation in immunity and tolerance
Julie Denoeud et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis
Camille L. Pittet et al.
JOURNAL OF NEUROINFLAMMATION (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Programmed Death-1 Pathway Limits Central Nervous System Inflammation and Neurologic Deficits in Murine Experimental Stroke
Xuefang Ren et al.
STROKE (2011)
Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
Michael Croft
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Stimulation of Glucocorticoid-Induced Tumor Necrosis Factor Receptor Family-Related Protein Ligand (GITRL) Induces Inflammatory Activation of Microglia in Culture
Heehong Hwang et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Troy Dillard et al.
PITUITARY (2010)
Accelerated Course of Experimental Autoimmune Encephalomyelitis in PD-1-Deficient Central Nervous System Myelin Mutants
Antje Kroner et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Target-Dependent B7-H1 Regulation Contributes to Clearance of Central Nervous Sysyem Infection and Dampens Morbidity
Timothy W. Phares et al.
JOURNAL OF IMMUNOLOGY (2009)
Constitutive Neuronal Expression of the Immune Regulator, Programmed Death 1 (PD-1), Identified During Experimental Autoimmune Uveitis
Ling Chen et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2009)
PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE
Bettina Schreiner et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
NGF-promoted axon growth and target innervation requires GITRL-GITR signaling
Gerard W. O'Keeffe et al.
NATURE NEUROSCIENCE (2008)
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells
Ana C. Anderson et al.
SCIENCE (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis
Laura L. Carter et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
CD40 express on by miroglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation
EA Ponomarev et al.
JOURNAL OF IMMUNOLOGY (2006)
CD40/CD154 interactions at the interface of tolerance and immunity
SA Quezada et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Paraneoplastic syndromes involving the nervous system
RB Darnell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: Modulation by FGF-2
C Reali et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2003)
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis
AD Salama et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Observing the invisible: successful tumor immunity in humans
RB Darnell et al.
NATURE IMMUNOLOGY (2003)
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8(+) T cell activation and cytolysis
N Rodig et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
CD40 expressed by human brain endothelial cells regulates CD4+T cell adhesion to endothelium
KM Omari et al.
JOURNAL OF NEUROIMMUNOLOGY (2003)
CD40 is expressed and functional on neuronal cells
J Tan et al.
EMBO JOURNAL (2002)
Share Paper
